Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma

Oncology

Volumn 71, Issue 5-6, 2007, Pages 354-360

  Topkan, Erkan ^a,c   Karaoglu, Aziz ^b  

^a INONU UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

Author keywords

Chemoradiotherapy; Loperamide; Octreotide; Refractory diarrhea

Indexed keywords

ATROPINE; CODEINE; CYTARABINE; DIPHENOXYLATE; FLUOROURACIL; IRINOTECAN; KAOLIN PECTIN; LOPERAMIDE; METHOTREXATE; OCTREOTIDE; PAREGORIC; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HOSPITALIZATION; HUMAN; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM CANCER; THERAPY DELAY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; COMBINED MODALITY THERAPY; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, SUBCUTANEOUS; LOPERAMIDE; MALE; MIDDLE AGED; OCTREOTIDE; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 35348870651     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108593     Document Type: Article

References (48)

1. Douglas HO Jr, Moertel CG, Mayer RJ: Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986;315:1294-1295.
2. Krook JE, Moertel CG, Gunderson LL: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-715.
3. Kollmorgen CF, Meagher AP, Wolff BG: The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 1994;220:676-682.
4. Miller RC, Martenson JA, Sargent DJ, et al: Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys 1998;41:593-598.
5. Kinsella TJ, Bloomer WD: Tolerance of the intestine to radiation therapy. Surg Gynecol Obstet 1980;151:273-284.
6. Wadler S, Benson AB, Engelking C, et al: Guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-3178.
7. Benson AB, Ajani JA, Catalano RB, et al: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926.
8. Levy MH: Constipation and diarrhea in cancer patients. Cancer Bull 1991;43:412-422.
9. Girinsky T, Rey A, Roche B, Haie C, et al: Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051-1056.
10. Sher ME, Bauer J: Radiation-induced enteropathy. Am J Gastroenterol 1990;85:121-128.
11. Cascinu S, Bichiaso E, Amadori D, et al: High dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer 2000;8:65-67.
12. Szilagyi A, Shrier I: Systemic review: the use of somatostatin or octreotide in refractory diarrhea. Aliment Pharmacol Ther 2001;15:1889-1897.
13. Cascinu S, Fedeli A, Fedeli SL, et al: Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology 1994;51:70-73.
14. Wood AJJ: Octreotide. N Engl J Med 1996;334:246-254.
15. Bailli-Johnson HR: Octreotide in the management of treatment-related diarrhea. Anticancer Drugs 1996;7(suppl 1):11-15.
16. Goumas P, Naxakis S, Christopoulou A, et al: Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 1998;3:50-53.
17. Zidan J, Haim N, Beny A, et al: Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001;12:227-229.
18. Gebbia V, Carreca I, Testa A, et al: Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993;4:443-445.
19. Morris JB, Guerrero NH, Furth NE, et al: Somatostatin attenuates ischemic intestinal injury. Am J Surg 1993;165:676-680.
20. Wang J, Zheng H, Sung CC, et al: The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys 1999;45:1289-1296.
21. Yavuz MN, Yavuz AA, Aydin F, et al: The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. Int J Radiat Oncol Biol Phys 2002;54:195-202.
22. Martenson JA, Bollinger JW, Sloan JA, et al: Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy. A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. J Clin Oncol 2000;18:1239-1245.
23. Dosik GM, Luna M, Valdivieso M, et al: Necrotizing colitis in patients with cancer. Am J Med 1979;67:646-656.
24. de Roy van Zuidewijn DBW, Schillings PHM, Wobbers TH, et al: Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Exp Mol Pathol 1992;56:96-107.
25. Milles SS, Muggia AL, Spiro HM: Colonic histologic changes induced by 5-fluorouracil. Gastroenterology 1962;43:391-399.
26. Rubin P: The Franz Buschke Lecture. Late effects of chemotherapy and radiation therapy. A new hypothesis. Int J Radiat Oncol Biol Phys 1984;10:5-34.
27. Ychou M, Douillard JY, Rougier P, et al: Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open label phase II study. Am J Clin Oncol 2000;23:143-148.
28. Gallagher MJ, Bereton HD, Rostock RA, et al: A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 1986;12:1565-1573.
29. Kornblau S, Benson AB, Catalano R, et al: Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 1995;10:298-308.
30. Darmasathaporn K, Sherwin RS, Cataland S, et al: Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980;92:68-69.
31. Kvols LK, Moertel CG, O'Connell MJ, et al: Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-666.
32. Darmasathaporn K, Racusen L, Dobbins JW: Effect of somatostatin on ion transport in the rat. J Clin Invest 1980;66:813-820.
33. Darmasathaporn K, Blinder HJ, Dobbins JW, et al: Somatostatin stimulates sodium and chloride absorption in the rat ileum. Gastroenterology 1980;78:1559-1565.
34. Dueno MI, Bai JC, Santangelo WC, et al: Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987;32:1092-1096.
35. Karalis K, Mastorakos G, Chrousos GP, et al: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994;93:2000-2006.
36. Maton PN, O'Dorisio TM, Howe BA, et al: Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1985;312:17-21.
37. Robinson EN Jr, Fogel R: SMS 201-995, a somatostatin analogue, and diarrhea in the acquired immunodeficiency syndrome AIDS. Ann Intern Med 1988;108:680-681.
38. Bianco JA, Higano C, Singer J, et al: The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 1990;49:1194-1195.
39. Mourad FH, Gorard D, Thillainayagam AV, et al: Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut 1992;33:1578-1580.
40. Darmasathaporn K, Gorelick FS, Sherwin RS, et al: Somatostatin decreases diarrhea in patients with short-bowel syndrome. J Clin Gastroenterol 1982;4:521-524.
41. Vecht J, Lamers CB, Masclee A: Long-term results of octreotide-therapy in severe dumping syndrome. Clin Endocrinol (Oxf) 1999;51:619-624.
42. Bonfils S, Rusniewzski P, Costil V, et al: Prolonged treatment of Zollinger-Ellison syndrome by long-acting somatostatin. Lancet 1986;i:554-555.
43. Petrelli NJ, Rodriguez-Bigas M, Rustum Y, et al: Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993;72:1543-1546.
44. Wang J, Zeng H, Sung CC, et al: The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys 1999;45:1289-1296.
45. Morris JB, Guerrero NH, Furth EE, et al: Somatostatin attenuates ischemic intestinal injury. Am J Surg 1993;165:676-680.
46. Warhurst G, Turnberg LA, Higgs NB, et al: Multiple G-protein-dependent pathways mediate the antisecretory effects of somatostatin and clonidine in HT29-19A colonic cell line. J Clin Invest 1993;92:603-611.
47. Ajani JA, Chesnut JR: Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer 1993,29A:2332-2333.
48. Wadler S, Haynes H, Wiernik PH: Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995;13:222-226.